Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy (clinicaltrials.gov) - Aug 13, 2026 - P1/2 | N=10 | Not yet recruiting | Sponsor: BreakBio Corp
New P1/2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PD-L1
|